SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Cancer " 1,596 found 🔀 AI-powered Shuffle
Merck’s cholesterol pill gets US FDA approval
Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s nod, bolstering the drugmaker’s efforts to diversify beyond its blockbuster cancer treatment Keytruda.
Scientists finally solved how a common gut bacterium triggers colon cancer
Researchers solved a long-standing mystery behind how a bacterial toxin associated with colorectal cancer damages the colon. The toxin first binds to a receptor called claudin-4, giving it access to attack the cells' protective barrier. After identifying this weak point, the team designed a decoy protein that successfully blocked the toxin in mice. The discovery could pave the way for new therapies to prevent inflammation and colon tumors.
This pet gecko could help scientists unlock the secrets of cancer
An unusual leopard gecko that naturally develops aggressive tumors may become an important new model for cancer research. Scientists found its tumors share key genetic changes with human cancers, offering a rare opportunity to study the disease as it develops naturally.
Cook Co. health officials call for Trump admin to do more in preventing colorectal cancer in young a
Sam Neill's ex says his cancer battle left him 'pretty sick' and 'compromised'
Sam Neill's former partner Laura Tingle says his \
Leonard Abramson, Health Care Innovator and Philanthropist, Dies at 93
He created U.S. Healthcare, one of the first H.M.O.s, and used his great wealth from the sale of the company for causes like advancing cancer research.
RWJBarnabas Health and Rutgers Cancer Institute Welcome First Patients at Melchiorre Cancer Center
RWJBarnabas Health and Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, officially welcomed its first patients today at the Melchiorre Cancer Center.
NBC host gives health update after previously revealing cancer diagnosis on air
She shared the news on her Instagram page on Sunday.
Bipartisan bill seeks to bolster AI use in pediatric cancer care
Members of the Childhood Cancer Caucus are proposing the Accelerating Innovation for Kids Act, aimed at fast-tracking the deployment of this tech in pediatrics.
Algorithm allows cancer patients to avoid CT scans for pulmonary embolism
There has been increased interest in finding alternative methods to diagnose pulmonary embolism in this patient population.
Man, 45, diagnosed with colorectal cancer shares his first symptom
Randy League was diagnosed with stage 3 colorectal cancer at 45 after feeling a sudden, sharp pain in his rectum.
Sam Neill’s Blood Cancer Explained and Last Health Updates Before Death
The family of the “Jurassic Park” star announced his death on Monday, adding that he was still “cancer free” when he died.
Do People Trust Science Anymore?
There are several psychological reasons why some people reject scientific consensus. How distant one feels psychologically from science increases the likelihood of rejection.
Pesticide makers stack wins against US environmental, public health groups
The U.S. Supreme Court handed a major legal victory to German agrichemical and pharmaceutical company Bayer last month when it reined in thousands of lawsuits accusing the German company of failing to warn users that glyphosate, the active ingredient in its Roundup weedkiller, causes cancer.
2nd PET scan changes treatment for nearly half of prostate cancer patients
Managing recurrent prostate cancer after first-line treatment remains a key clinical challenge, experts write in The Journal of Nuclear Medicine.
Simple sitting change linked to lower risk of cancer death, study finds
Each additional hour of prolonged sedentary behavior was linked to a 10% higher cancer death risk, but brief movement breaks may significantly reduce it.
More people are focusing on gut health as fermented foods gain popularity
More people are focusing on their gut health as colorectal cancer rises among young adults and personalized gut microbiome treatments become increasingly popular.
More people are focusing on gut health as fermented foods gain popularity
More people are focusing on their gut health as colorectal cancer rises among young adults and personalized gut microbiome treatments become increasingly popular.
People have been fermenting food for millennia. Here's why more people are focused on gut health now
More people are focusing on their gut health, as fibermaxxing goes mainstream, colorectal cancer rises among young adults and personalized gut microbiome treatments become increasingly popular.
Woman, 45, Underwent the First Robotic Single-Port Nipple-Sparing Mastectomy Performed in the U.S by a Robot Named Carol
Vicky Pan, a mom of two, was diagnosed with aggressive, fast-growing triple-negative breast cancer that had already spread to her lymph nodes
OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
The Trump administration has a fight on its hands as it pushes forward with a plan to exert greater political control over government funding of science. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses […]
Radiation oncology providers form nonprofit network in bid to preserve independence
"Physicians should not have to surrender their independence to survive, and families deserve care close to home," those involved with the new Anoma Cancer Collective say.
LSU and FMOL Health award research grants targeting state’s critical health needs
LSU and FMOL Health | Our Lady of the Lake have awarded more than $1.6 million in research grants to seven teams through the Collaboration in Action Program, or CAP, supporting projects aimed at solving critical health challenges in Louisiana. The funded research focuses on areas including cancer, trauma care, chronic disease, obesity, sports medicine, […]
Scientists finally crack nature's secret for building better cancer drugs
Researchers have cracked the code behind bacteria's ability to naturally manufacture multiple versions of powerful anti-cancer drugs. The discovery could make it much easier to engineer new cancer treatments inspired by nature, including improved versions of existing medicines.
From cancer survivor to chief of AI at UCLA Health
While learning about brain tumors in medical school, Dr. Paul Lukac discovered he had one.
WHO calls for urgent action as new cancer cases are projected to nearly double by 2050
Millions of people are facing physical, emotional and financial toll of cancer, a disease that claims more than 26 000 lives every day, according to a report released today by the World Health Organization (WHO). With an estimated 20.6 million new cases and close to 10 million deaths annually, cancer remains the second leading cause of death globally, after cardiovascular disease.
Cancer cases worldwide will soar in the coming decades, a report finds. Here’s why.
The World Health Organization tempered optimism about improvements in cancer treatment and said global health care inequities are driving more cases and deaths.
Creatine doesn't just build muscle. It may also help fight cancer
Scientists have discovered that creatine may strengthen one of the immune system's most important cancer-fighting pathways by energizing dendritic cells that activate killer T cells. The promising results could eventually help make immunotherapy more effective, but they have not yet been tested in human patients.
RFK Jr. targets health panel controlling cancer screenings
The task force plays a major role in determining how easily Americans can access screenings for cancer and other illnesses.
Microbiome science merges with oncology for better cancer treatments
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.
Commentary: Night shifts are deadly, not just inconvenient
During his 26 years as a night-shift nurse, Ed Collum watched colleagues nod off mid-conversation, battle chronic illnesses and, too often, die young from cancer, stroke or suicide. Collum puts
An Antarctic sea squirt could help treat melanoma
The organism may help produce a cancer-killing toxin
CaroMont Health Opens CaroMont Hematology & Oncology in Belmont
CaroMont Health has opened CaroMont Hematology & Oncology in Belmont, expanding access to cancer and blood disorder care across the region. Located in the CaroMont Health Medical Pavilion on the campus of CaroMont Regional Medical Center in Belmont, the practice offers physician visits, infusion therapy and laboratory services in one convenient location, along with comprehensive hematology and medical oncology care including chemotherapy, immunotherapy, targeted therapy, hormone therapy and survivorship support. The opening is part of CaroMont Health's $200 million investment in cancer care, the second largest investment in the health system's history, which will double its oncology capacity across the region.
New workflow tool gives scientists a clearer view of how DNA is regulated
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at NUS have developed a new method that allows scientists to better understand how DNA is organized and regulated inside cells. ...
Researchers Develop AI Test to Predict Recurrence of Breast Cancer
Breakthrough offers potential for faster, less costly predictions to help guide treatment
Scientists solve a 30-year rye pollen mystery that could transform cancer research
Scientists have finally solved a nearly 30-year-old mystery surrounding two unusual molecules found in rye pollen that once showed an intriguing ability to help animals fight tumors. By determining their exact 3D structures, researchers have unlocked the blueprint needed to investigate how these natural compounds interact with the immune system and which parts may be responsible for their cancer-fighting effects.
New photos show touching moment Kate Middleton hugged her children after grueling 24-hour mountain climb
Kate Middleton completed the Three Peaks Challenge for a cancer charity and quietly donated to an 11-year-old wheelchair user she met during the climb.
Scientists Wipe Out 99% of Cancer Cells in Lab Using Vibrating Molecules
No chemo or radiation.
Dartmouth Health launches virtual cancer support group for survivors
Online forum connects patients navigating life after diagnosis
Dartmouth Health launches virtual cancer support group for survivors
Online forum connects patients navigating life after diagnosis
Cancer Health: HIV raises hepatitis C liver disease risk in women more than men
Women with HIV and HCV face higher odds of cirrhosis and liver decompensation but not liver cancer.
Sunburn in children can cause skin cancer later in life. How to protect them
A dermatologist and a cancer research expert outline the skin damage childhood sunburn can cause later in life, and advise on sun safety.
Shore Regional Health Cancer Center adds community outreach coordinator
EASTON — The Cancer Center at University of Maryland Shore Regional Health recently welcomed Catalina Billings as coordinator of community outreach, a new position designed to provide up-to-date cancer information
'Tanmaxxing' trend could come at a dangerous cost, skin cancer experts warn
A dermatologist warns that "tanmaxxing" is causing DNA damage, calling the Gen Z tanning trend a "visible distress signal" rather than a wellness upgrade.
Stanley M. Gartler, Pioneer in Cancer Research, Dies at 102
He provided the first convincing evidence that cancerous tumors develop from a single mutated cell and later helped expose contamination by cells taken from Henrietta Lacks.
Scientists Just Unlocked an Endless Army of Cancer-Fighting Cells
The 'big eaters' are on the way.
Scientists Just Unlocked an Endless Army of Cancer-Fighting Cells
The 'big eaters' are on the way.
David J. Skorton: Make Your Voice Heard to Protect Science-Driven Funding Decisions in U.S. Research Policy
David J. Skorton: Make Your Voice Heard to Protect Science-Driven Funding Decisions in U.S. Research Policy / AAMC, cancer, David J. Skorton, OncoDaily,
A hidden weakness in deadly cancers could lead to powerful new treatments
A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for decades. Scientists found that tumors lacking the RB gene become critically dependent on the protein E2F3 for survival. Blocking E2F3 shut down tumor growth in laboratory models, and existing FDA-approved drugs may be able to exploit this vulnerability. The discovery could pave the way for faster development of more effective therapies.
Breast cancer
WHO fact sheet on breast cancer, including information on prevalence, risk factors, symptoms, management, global impact and WHO's work on breast cancer.
Zeeland Street owner says fresh food aided recovery: ‘I had to kick Mr. Cancer to the curb.’
Zeeland Street owner Stephanie Phares shares her journey of battling Stage 3 lung cancer while continuing to run her beloved Baton Rouge restaurant. "It kept me with a routine. There was no time to feel fearful or scared," she said.
Once a source of national pride, Cuba’s healthcare system declines as energy shortages deepen crisis
Irisleydis Tristá, a cancer patient in Cuba, has been unable to get a crucial CT scan for seven months because the machine at Havana’s leading hospital is broken.
Following High-Court Victory, Bayer Separates Roundup Business
The Supreme Court handed Bayer a massive win last week in its attempts to beat back lawsuits alleging its Roundup weedkiller causes cancer. Now, the German company is separating Roundup into its ow
If we lose our coverage, we lose our lives
By Thomas Buckley My oncologist asked: “Polycythemia Vera. Do you know what that means?” Earlier, I lived in blissful ignorance, unaware I potentially carried a myeloproliferative neoplasm encoded within my DNA. “Yes,” I answered, “A rare form of blood cancer, incurable, not necessarily fatal, provided it’s treated.” At 31, I thought I had life figured […]
Simpler lung cancer screening criteria could capture more patients likely to benefit
New research published in JAMA Internal Medicine compared current USPSTF criteria to a potential shift toward total years smoked, rather than pack years.
Children’s Hospital Los Angeles’ 2026 TSRI Science Day Highlights Advances in Cancer Biology
June 17 saw more than 400 scientists, clinicians, research staff, and other Children’s Hospital Los Angeles team members come together for The Saban Research Institute’s (TSRI) yearly symposium and poster session—Science Day 2026.
FMOL Health pegs Cancer Institute investment at $70M, shares timeline
FMOL Health expects to invest roughly $70 million to transform the former Bone & Joint Clinic of Baton Rouge building into a new home for the Our Lady of the Lake Cancer Institute, according to E.… Already an INSIDER? Sign in. Already an INSIDER? Sign in
Vanderbilt Health performs nation’s first breast cancer surgery using intraoperative PET-CT scan technology
The novel imaging technology provides surgical teams with a real-time view of tumor margins in the operating room.
Jon and Mindy Gray Bet on AI Science Research to Prevent Cancer
Blackstone Inc. President Jon Gray has steered his firm to more artificial-intelligence investments, and the same is true with his science philanthropy.
Radiology providers must pay $7M, modify policies after breast cancer miss
Radiologist Henry C. Lusane, MD, with Acumen Medical Imaging, interpreted the scans, reporting the mass as benign, a mistake later leading to a terminal cancer diagnosis.
Doctors thought man had brain cancer — they found live tapeworms instead
Doctors suspected metastatic brain cancer in a 60-year-old man, but scans revealed pork tapeworm larvae causing neurocysticercosis.
Does a recent U.S. Supreme Court decision affect how Minnesota can warn of pesticide health dangers?
The question stemmed from a lawsuit about cancer risks associated with Monsanto's widely-used weed killer, Roundup.
Scientists discover an unexpected way to make pancreatic cancer cells self-destruct
Researchers tested experimental PCAI compounds against pancreatic cancer cells and found they had powerful anticancer effects. One leading compound blocked more than 90% of cancer cell migration, suggesting it could help prevent the spread of tumors. Rather than suppressing cancer signaling, the treatment hyperactivated key pathways until the cells essentially self-destructed.
After months of unanswered pain, a Philly woman learned she had Stage 3 colon cancer. Now she’s pushing for equitable care
Medical advances mean that more people are surviving cancer. But not everyone is benefiting from those gains equally, a new report shows.
Doctors urge men to prioritize preventative care during Men’s Health Month
One in eight men will be diagnosed with prostate cancer in their lifetime, but many won’t know they’re at risk until it’s too late.
Catherine completes Three Peaks Challenge to 'explore life beyond' cancer diagnosis
The Princess of Wales did the endurance event to raise awareness about "holistic healthcare" for cancer patients.
Huntsville health department hosting no-cost prostate exams
Prostate cancer can be treated and cured with early screenings, according to Dr. Thomas Moody with the Urology Health Foundation.
Rise in cancer in younger adults may be explained by faster 'biological aging,' early study hints
Researchers report that younger adults with older‑than‑expected biological ages are more likely to develop early‑onset lung, gastrointestinal and uterine cancers, but more research is needed.
Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE
Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE / AstraZeneca, BioNTech SE, cancer, OncoDaily, Oncology, Vikas Sehdev
Tung-Sung Tseng: Honored to Receive the Team Science Champion Award for Tobacco-Related Cancer Research
Tung-Sung Tseng: Honored to Receive the Team Science Champion Award for Tobacco-Related Cancer Research / cancer, LTCI, OncoDaily, Oncology, Team Science
The sky is not falling. Americans are getting healthier.
Despite declining obesity and heart disease rates, increasing cancer survival rates, and a record high life expectancy, politicians from both parties are pushing costly and ineffective policies to …
The fittest founder in the room got cancer. Here's how he used AI to fight back.
When confronted with cancer, Connor Christou fed everything tied tied to his regime — blood results, scan data, wearable output, journal entries — into Claude.
New vitamin B12 therapy shows promise against deadly brain cancer
Researchers have identified a vitamin B12–based compound that can cross the blood-brain barrier and home in on glioblastoma tumors. In animal studies, the compound accumulated preferentially in tumor tissue and delivered sustained nitric oxide directly to cancer cells. It also worked synergistically with existing glioblastoma treatments, significantly enhancing their tumor-fighting effects.
Burglars steal from Grand Forks business, cancer fundraiser
The owner of An Elegant Affair says burglars stole merchandise, cash and donations collected for an employee battling cancer.
AI-assisted colonoscopy enhances polyp detection at UT Health San Antonio Multispecialty and Research Hospital
Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu Content provided by Kristen Zapata SAN ANTONIO, June 29, 2026 – A routine colonoscopy may last less than an hour. But what happens during that procedure can change, or even save, a life years before cancer ever has a chance to develop. Physicians at The University of Texas at San […]
Bridget and Mike Chiodo on Strong Bond, Health Struggles, Family
Influencer Bridget Bahl and her husband Dr. Mike Chiodo join TODAY’s Jenna Bush Hager and Sheinelle Jones to celebrate Bridget becoming cancer free, open up about their steadfast bond and share an update on their dream of starting a family.
Andy Cohen cries as he mourns 28-year-old 'WWHL' producer who died of brain cancer
Andy Cohen became emotional mourning 'Watch What Happens Live' production manager Kyra Samson, 28, who died of brain cancer earlier this week.
OHSU advances massive leap in medical science with cellular therapies
Patients are benefiting from CAR-T to treat neurodegenerative diseases, cancer, lupus and other autoimmune conditions.
Supreme Court rules in weedkiller cancer case
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news
Most Patients Want Docs To Break Cancer News Directly, Not Through Portal Messaging
By Dennis Thompson HealthDay ReporterFRIDAY, June 25, 2026 (HealthDay News) — People are becoming more comfortable communicating with their doctor through clinics’ patient portals. Folks use the portals to ask their doc questions and even to review the results of recent medical tests. But there are ...
Bayer wins in US court, but at what cost to public health?
A landmark US Supreme Court ruling protects Bayer from thousands of lawsuits linked to its Roundup weedkiller. Plaintiffs alleged the German agrochemical giant failed to warn users about potential cancer risks.
UT Health San Antonio researcher receives $400,000 Komen grant to study therapeutic yoga for breast cancer survivors
UT Health San Antonio researcher receives $400,000 Komen grant to study therapeutic yoga for breast cancer survivors
UT Health San Antonio researcher receives $400,000 Komen grant to study therapeutic yoga for breast cancer survivors
Amelie G. Ramirez, DrPH, MPH, to work with Hispanics in South Texas Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu Content provided by Cliff Despres SAN ANTONIO, June 25, 2026 – Amelie G. Ramirez, DrPH, MPH, a cancer researcher at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, is […]
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Supreme Court sides with big business in Roundup cancer risk fight
The ruling is also a victory for the Trump administration and a defeat for the Make America Healthy Again movement.
GLP-1 and reduced cancer risk discovery earns UT Health San Antonio fellow prestigious Helio NextGen Disruptor Award
Colton Frisco Jones, MD, a 2nd-year fellow at the Mays Cancer Center at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago.
First-of-its-kind discovery earns UT Health San Antonio Mays Cancer Center fellow prestigious Helio NextGen Disruptor Award
Colton Frisco Jones, MD, a 2nd-year fellow at the Mays Cancer Center at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago.
Supreme Court sides with big business in Roundup cancer risk fight
The ruling is also a victory for the Trump administration and a defeat for the Make America Healthy Again movement.
Keith Flaherty: Translating Science into Medicine
Keith Flaherty: Translating Science into Medicine / American Association for Cancer Research, cancer, Keith Flaherty, Massachusetts General Hospital,
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.
Bacteria-killing viruses redirect vaccine immunity to destroy cancer
Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
Imaging-related burdens may be keeping some from completing cancer screenings
Targeted interventions could help reduce pre-test anxiety, improve the physical screening experience, and address structural barriers in underserved settings.
Tongue Cancer Survivor Reunites with ICU Doctor Who Helped Save Her Life
After a life-threatening complication from tongue cancer surgery led to septic shock and organ failure, high school teacher Jennifer Quick spent nearly a month in the ICU at Atrium Health.
Oklahoma ACA insurer Mending to end health plans after this year
A health policy analyst says the move comes amid a broader trend of insurer exits as several federal policy changes fuel declining enrollment.
As cancer death rates plunge, clear disparities remain, new report says
Black and American Indian/Alaska Native communities have the highest cancer rates of any racial or ethnic group in the U.S.
Bills legend Jim Kelly provides update on condition after stroke
After beating cancer in 2019, Bills legend Jim Kelly revealed that he suffered a setback while recovering from a spring stroke.
Meet the doctor building tiny tools for big science breakthroughs
UCLA's Steven Jonas uses nanotechnology in his lab to explore cancer and other disease-fighting tools.
Vanderbilt Health lands three of 35 Susan G. Komen research grants
Komen is the largest nonprofit funder of breast cancer research outside of the U.S. government, having invested more than $1.1 billion in research since its founding.
RWJBarnabas Health and Rutgers Cancer Institute Unveil the Melchiorre Cancer Center, Expanding Access to World-Class Cancer Care
Today, RWJBarnabas Health and Rutgers Cancer Institute, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, unveiled the Melchiorre Cancer Center at Cooperman Barnabas Medical Center.